Table 1.

Ventricular tachycardia and ventricular fibrillation post COVID-19 vaccination as reported in the Vaccine Adverse Event Reporting System

	Ventricular tachycardia	Ventricular fibrillation
All ventricular arrhythmias
Total events	349	167
Johnson & Johnson	12 (3.44)	19 (11.38)
Moderna	207 (59.31)	82 (49.10)
Pfizer/BioNTech	213 (61.03)	89 (53.29)
New onset ventricular arrhythmia
Total events	8	3
Johnson & Johnson	—	2 (66.67)
Moderna	4 (50)	—
Pfizer/BioNTech	6 (75)	1 (33.33)
Male
Total events	204	121
Johnson & Johnson	5 (2.45)	17 (14.05)
Moderna	130 (63.73)	60 (49.59)
Pfizer/BioNTech	109 (58.33)	61 (50.41)
Female
Total events	145	45
Johnson & Johnson	7 (4.83)	2 (4.44)
Moderna	77 (53.10)	22 (48.89)
Pfizer/BioNTech	94 (64.83)	26 (57.78)
<7 d for ventricular arrhythmia onset since vaccination
Total events	134	71
Johnson & Johnson	4 (2.99)	4 (5.63)
Moderna	82 (61.19)	28 (39.44)
Pfizer/BioNTech	65 (61.19)	39 (54.93)
≥7 d for ventricular arrhythmia onset since vaccination
Total events	213	94
Johnson & Johnson	8 (3.76)	15 (15.96)
Moderna	125 (58.69)	54 (57.45)
Pfizer/BioNTech	146 (68.54)	48 (51.06)
Following first dose
Total events	141	74
Johnson & Johnson	12 (8.51)	12 (16.22)
Moderna	63 (44.68)	27 (36.49)
Pfizer/BioNTech	69 (48.94)	35 (47.30)
Following second or following doses
Total events	234	85
Johnson & Johnson	—	1 (1.18)
Moderna	125 (53.42)	46 (54.12)
Pfizer/BioNTech	125 (53.42)	41 (48.24)
Age <40 y
Total events	56	21
Johnson & Johnson	3 (5.36)	1 (4.76)
Moderna	21 (37.50)	10 (47.62)
Pfizer/BioNTech	42 (75.00)	11 (52.38)
Age ≥40 y
Total events	293	146
Johnson & Johnson	9 (3.07)	18 (12.33)
Moderna	186 (63.48)	72 (49.32)
Pfizer/BioNTech	171 (58.36)	78 (53.42)

Values are n or n (%).